Investing

Goldman Sachs Has 5 Buy-Rated Stocks Under $10 With Up to 600% Upside Potential

Genius Sports offers technology infrastructure for the collection, integration and distribution of live data of sports leagues; streaming solutions, comprising of technology, automatic production and distribution for sports to commercialize video footage of their games; and end-to-end integrity services to sports leagues, such as full-time active monitoring technology, which uses mathematical algorithms to identify and flag suspicious betting activity in global betting markets, as well as full suite of online and offline educational and consultancy services.

Genius Sports also provides live sports data collection; pre-game and in-game odds feeds; risk management services, including customer profiling, monitoring of incoming bets, automated acceptance and rejection of bets, and limit setting; live streaming services; creation, delivery and measurement services for personalized online marketing campaigns; and fan engagement widgets for digital publishers that offer live game statistics and betting-related content.

The Goldman Sachs price objective is $24. The lower $10.83 consensus target. With Genius Sports stock closing on Friday at $4.53, hitting the Goldman Sachs target would be a gain of more than 400%.

Kronos Bio

This microcap biotech may be the biggest winner of all the Goldman Sachs Buy-rated stocks under $10. Kronos Bio Inc. (NASDAQ: KRON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer therapeutics.

The company’s product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients.

The company has planned a registrational Phase 3 clinical trial of entospletinib in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin-dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in Phase 1/2 clinical trial.

The staggering $50 Goldman Sachs price target compares with the $40.25 consensus and a closing share price on Friday of $7.01. Hitting the Goldman Sachs target would be a 600% gain.

Planet Labs PBC

This is another micro-cap stock that could surge with positive earnings. Planet Labs PBC (NYSE: PL) designs, builds and operates an earth observation fleet of imaging satellites that capture and compile data. It serves agriculture, civil government, defense and intelligence, drought response, education and research, energy and infrastructure, finance and insurance, forestry and land use, mapping, maritime, sustainability and federal sectors.

Sponsored: Find a Qualified Financial Advisor

Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.